Sexual function.
Conditions
Interventions
Intervention 1: Intervention group: oral folic acid tablets, 5 mg, 1 tablet daily for 8 weeks constructed by Rouz Darou factory. Intervention 2: Control group: placebo tablets, 1 tablet daily, for 8
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Being Iranian Lack of speech, hearing or mental disorders that prevent communication with the researcher It's been at least a year since they stopped menstruating Being in the first ten years of menopause being sexually active Lack of folic acid deficiency (self-report) Lack of any type of anemia (based on lab test) Not taking hormone replacement therapy Not using any chemical or herbal medicines (Gensing, Vitagnos, Maca, Femaxite capsules, Flibanserin) that affect sexual function (according to the woman) Lack of sexual problems in their spouses (such as erectile dysfunction or premature ejaculation, according to the self-report) No history of hysterectomy and oformorectomy, cystosel, rectosell, and mastectomy Lack of known mental illness in women and their spouses according to the self-report Any addicted to cigarettes, alcohol or drugs in women and their spouses Any history of known chronic diseases such as high blood pressure, diabetes, hyperlipidemia, asthma, weakening of the immune system, etc., according to the medical record Any specific incident or crisis in their life such as death or incurable disease in family members, change of residency and loss of job since 6 months ago Not using herbal teas while taking the medicine Not using anti convulsants Not being depressed, anxious or stressed (based on the results of the DOS questionnaire) Menopause occurs naturally (not followed by ovarectomy) Premature menopause does not occur Not having body mass index above 30
Exclusion criteria
Exclusion criteria: Possible sensitivity to folic acid
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The outcome variable is the sexual function, which contains the body reacts at different stages of the sexual response cycle and will be measured by the Women's Sexual Function Index Questionnaire. Timepoint: At the beginning of the study (before the intervention), 4 and 8 weeks after the intervention. Method of measurement: The outcome measure variable will be evaluated with theFemale Sexual Function Index which is an indicator for women's sexual function. This questionnaire contains 19 questions and measures sexual function in 6 independent areas of sexual desire, sexual arousal (psychological stimulation), vaginal moisturizing, orgasm, satisfaction and sexual pain. The total score range is between minimum of 2 and a maximum of 36, and a higher score indicates a more desirable sexual function. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMahnaz Asadi
Shahid Beheshti University of Medical Sciences
Outcome results
None listed